Eyevensys

Eyevensys is a privately held, clinical-stage biotechnology company. Our first-in-class, non-viral vector gene therapy, sustained drug delivery system offers a new approach to treating major ophthalmic conditions, including chronic non-infectious uveitis, degenerative retinal diseases, retinal vascular diseases, and macular edemas. Together, these illnesses account for the vast majority of vision loss around the globe and significantly impact quality of life for patients of all ages.

Revolutionizing the Treatment of Eye Disease
The Eyevensys technology enables therapeutic proteins to be produced inside the eye—by the eye itself—providing long-lasting treatment effects. It works by administering DNA plasmids directly into the ciliary muscle in the eye, using a process called electrotransfection.

Our novel non-viral gene therapy, sustained ocular drug delivery approach is minimally invasive and offers considerable safety and cost advantages over viral vector gene therapies. It is also more convenient than other intraocular drug delivery approaches, which require repeated intravitreal injection or the insertion of implanted devices.

Видео Eyevensys канала Logan Gilpin